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Abstract
Galectin-1 contains a carbohydrate-recognition domain (CRD) as a member of the lectin family. Here, we investigated
whether galectin-1 regulates adipogenesis and lipid accumulation. Galectin-1 mRNA is highly expressed in metabolic
tissues such as the muscle and adipose tissues. Higher mRNA expression of galectin-1 was detected in white adipose
tissues (WATs) of mice that were fed a high-fat diet (HFD) than in those of mice fed a normal-fat diet (NFD). Protein
expression of galectin-1 also increased during adipocyte differentiation. Galectin-1 silencing inhibited the
differentiation of 3T3-L1 cells and the expression of lipogenic factors, such as PPARγ, C/EBPα, FABP4, and FASN at both
mRNA and protein levels. Lactose, an inhibitor by the binding with CRD of galectin-1 in extracellular matrix, did not
affect adipocyte differentiation. Galectin-1 is localized in multiple cellular compartments in 3T3-L1 cells. However, we
found that DMI (dexamethasone, methylisobutylxanthine, insulin) treatment increased its nuclear localization.
Interestingly, galectin-1 interacted with PPARγ. Galectin-1 overexpression resulted in increased PPARγ expression and
transcriptional activity. Furthermore, we prepared galectin-1-knockout (Lgals1−/−) mice and fed a 60% HFD. After
10 weeks, Lgals1−/− mice exhibited lower body weight and gonadal WAT (gWAT) mass than wild-type mice. Fasting
glucose level was also lower in Lgals1−/−mice than that in wild-type mice. Moreover, lipogenic genes were
significantly downregulated in the gWATs and liver tissues from Lgals1−/− mice. Pro-inflammatory cytokines, such as
CCL2, CCL3, TNFα, and F4/80, as well as macrophage markers, were also drastically downregulated in the gWATs and
liver tissues of Lgals1−/− mice. In addition, Lgals1−/−mice showed elevated expression of genes involved in
thermogenesis in the brown adipose tissue. Collectively, galectin-1 exacerbates obesity of mice fed HFD by increment
of PPARγ expression and activation. Our findings suggest that galectin-1 could be a potential therapeutic target for
obesity and needed further study for clinical application.
Introduction
Galectins are a family of proteins that bind to
β-galactoside. All galectins have a conserved
carbohydrate-recognition domain (CRD), consisting of
approximately 130 amino acids1. Galectins are localized in
extra- and intra- cellular compartments, and are involved
in cell adhesion, cell cycle progression, apoptosis,
inflammation, and cell growth2. Most studies on galectins
have focused on cancer and inflammatory disorders3.
Galectins are also involved in metabolic diseases such as
obesity and diabetes4. For example, the role of galectin-
124,5 and galectin-36 in adipocyte differentiation and
obesity has been already investigated.
Galectin-1 has been studied for its involvement in
cancer progression and inflammation7,8. Galectin-1
overexpression promotes cell transformation by increas-
ing membrane anchorage and oncogenic H-RAS signal
transduction9. Galectin-1 induces apoptosis in activated
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CD4+ and CD8+ T cells10, and promotes angiogenesis by
stimulating vascular endothelial cell proliferation and
migration11. Interestingly, a previous study was investi-
gated galectin-1 as a novel adipokine during adipocyte
differentiation12. Galectin-1 is also known as a lipid
droplet-associated protein in primary mouse adipocytes13.
A recent report demonstrated that treating 3T3-L1 cells
with thiodigalactoside (TDG), an inhibitor of galectins,
retarded adipocyte differentiation. In addition, TDG-
treated rats exhibited reduced body weight and white
adipose tissue (WAT) mass, suggesting that TDG treat-
ment increases the resistance to high-fat diet (HFD)-
induced obesity14. These findings suggested that galectin-
1 might be positively associated with adipocyte differ-
entiation and obesity. However, the underlying molecular
mechanisms are not yet fully understood.
In this study, we demonstrated that galectin-1 was
highly expressed in the mouse adipose tissue and further
increased during adipocyte differentiation and lipid
accumulation. Therefore, we explored the mechanism by
which galectin-1 regulates adipogenesis and obesity. To
this end, preadipocyte 3T3-L1 cells were used, and the
metabolic phenotype of galectin-1-deficient (Lgals1−/−)
mice exposed to an obesogenic HFD was characterized.
Results
Galectin-1 is upregulated during adipocyte differentiation
and predominantly expressed in mouse adipose tissue
To determine the in vivo distribution of galectin-1, var-
ious mouse organs were examined by RT-PCR analysis (Fig.
1a). Galectin-1 was more highly expressed in metabolic
tissues, such as the muscle and adipose tissue, than in other
organs. Moreover, the level of galectin-1 mRNA and protein
was higher in white adipose tissues from obese mice, which
were fed a 60% high-fed diet (HFD) for 12 weeks, compared
to those of normal-fat diet (NFD) fed mice (Fig. 1b).
We measured the changes in galectin-1 expression
levels during the differentiation of pre-adipocyte 3T3-
L1 cells to adipocytes (Fig. 1c). The cells were treated with
DMI (dexamethasone, methylisobutylxanthine, insulin)
and differentiated for 10 days. Galectin-1 expression, as
well as the expression of peroxisome proliferator-
activated receptor gamma (PPARγ) and fatty acid syn-
thase (FASN), two markers of adipocyte differentiation,
increased during adipocyte differentiation.
To study the role of galectin-1 in adipocyte differ-
entiation, the corresponding gene was silenced by trans-
fecting 3T3-L1 cells with a galectin-1-specific small
interfering RNA (siRNA), followed by cell differentiation
for 6 days (Fig. 1d). Galectin-1-depleted 3T3-L1 cells
showed significantly delayed adipocyte differentiation and
lipid accumulation, compared to control cells (Fig. 1e).
Lipid accumulation was also significantly dropped by
galecin-1 depletion at day 6 (Fig. 1f). These results
suggested that galectin-1 regulated adipocyte differentia-
tion and lipid accumulation.
Galectin-1-depleted 3T3-L1 cells exhibit retarded
adipocyte differentiation
Galectin-1 depletion reduced mitotic clonal expansion,
which was measured 48 h after adipogenic induction
(Fig. 2a). The impact of galectin-1 depletion on mRNA
(Fig. 2b) and protein expression (Fig. 2c) of lipogenic
factors, such as PPARγ, CCAAT enhancer binding pro-
tein alpha (C/EBPα), FASN, and fatty acid-binding protein
4 (FABP4), was also examined after adipocyte differ-
entiation. The expression of these lipogenic factors was
attenuated by galectin-1 depletion, at both mRNA and
protein levels. These data suggested that galectin-1 was
essential for adipocyte differentiation.
Next, the effect of extracellular-localized galectin-1 on
adipocyte differentiation was investigated (Fig. 2d and e).
Treatment of 3T3-L1 cells with lactose, an inhibitor of
galectin-1 by binding CRD, at concentrations up to
100mM did not affect cell differentiation. It suggested
that galectin-1-mediated regulation of adipocyte differ-
entiation did not occur through an extracellular CRD
binding mechanism.
Galectin-1 interacts with PPARγ and increases its
expression and transcriptional activation
We examined the subcellular localization of galectin-1
during adipocyte differentiation (Fig. 3a and b). Total
galectin-1 expression was found to increase after DMI
treatment. Interestingly, the nuclear localization of
galectin-1 significantly increased in a time-dependent
manner, as did that of PPARγ (Fig. 3b). Co-localization of
galectin-1 and PPARγ was detected in nucleus after DMI
treatment (Fig. 3a).
Therefore, we performed immunoprecipitation assays
and determined that galectin-1 and PPARγ interacted
with each other (Fig. 3c). Overexpression of galectin-1
also increased the protein expression level of endogenous
PPARγ (Fig. 3d). Moreover, overexpression of galectin-1
significantly increased the PPARγ transcriptional activa-
tion, indicated by the increment of PPAR-response ele-
ment (PPRE) activation (Fig. 3e). These data suggested
that DMI treatment increased galectin-1 expression in
nucleus, and that galectin-1 interacted with PPARγ and
promoted its expression and transcriptional activation.
Lgals1−/− mice show resistance to HFD-induced obesity
To confirm the role of galectin-1 in an in vivo mouse
model of obesity, male wild-type (Lgals1+/+) and galectin-1
knockout (Lgals1−/−) mice (n= 5 per group) were fed a
high-fat diet (HFD) containing 60% fat for 10 weeks
(Fig. 4a). The body weights were not significantly different
between those from Lgals1−/− mice and wild-type mice fed
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normal-fat diet (NFD) (Fig. 4b and c). However, Lgals1−/−
mice exhibited smaller body size (Fig. 4b) and lower body
weights than those of wild-type mice after exposure to the
HFD (Fig. 4c), even though the food intake did not sig-
nificantly differ between the two groups (Fig. 4d). The
weight of mouse tissues involved in fat metabolism, i.e.,
WAT, brown adipose tissue (BAT), and liver tissues, was
also measured (Fig. 4e). Both gWAT and iWAT as per body
weight ratio were decreased in HFD-fed Lgals1−/− mice,
compared to those from HFD-fed wild-type mice. Inter-
estingly, the relative BAT weight increased in Lgals1−/−
mice fed a HFD. No differences were observed in liver
weight between the groups. Moreover, because obesity is
known to increase the risk of type-2 diabetes mellitus
(T2D) and hyperlipidemia, the serum levels of glucose,
triglycerides, and free fatty acids were determined (Fig. 4f).
The fasting glucose level was lower in HFD-fed Lgals1−/−
mice than HFD-fed wild-type mice, although the levels of
triglycerides and free fatty acids did not differ.
Lgals1−/− mice exhibit decreased adiposity and altered
expression of genes involved in lipid metabolism and
thermogenesis
The gWATs of HFD-fed Lgals1−/− mice exhibited smaller
size and weight than those of wild-type mice (Fig. 5a). We
observed that adipocytes in gWAT were smaller in Lgals1−/−
mice than those in wild-type mice (Fig. 5b). HFD-fed
Lgals1−/− mice also showed lower iWAT weight than that of
their wild-type counterparts (Fig. 5e). The expression levels
of genes, which were involved in fatty acid uptake, and
lipogenesis were found to be significantly decreased in both
gWATs and iWATs from HFD-fed Lgals1−/− mice (Fig. 5c
and f). Obesity is known to cause macrophage infiltration
and elevated levels of pro-inflammatory cytokines in
WATs15. Therefore, the expression of F4/80, a macrophage
marker, and pro-inflammatory cytokines, such as TNFα,
CCL2 and CCL3 was measured (Fig. 5d and g). It revealed
that they were significantly downregulated in both gWATs
and iWATs from HFD-fed Lgals1−/− mice.
Fig. 1 Galectin-1 expression during adipocyte differentiation and in mouse adipose tissues. a The expression of galectin-1 mRNA in mouse
tissues was analyzed by RT-PCR. β-actin mRNA expression was used as a loading control. b The level of galectin-1 mRNA and protein was analyzed by
quantitative RT-PCR and western blotting in gonadal white adipose tissues (gWATs) and inguinal (iWATs) from mice fed a normal-fat diet (NFD) or a
high-fat diet (HFD) for 12 weeks. Data are presented as the mean ± standard error of the mean (SEM). *p < 0.05 for the NFD group (n= 5) vs. the HFD
group (n= 6). c The protein level of galectin-1 and lipogenic proteins, such as PPARγ and FASN was analyzed by western blotting during DMI
(dexamethasone, methylisobutylxanthine, insulin) induced differentiation of preadipocyte 3T3-L1 cells. β-actin expression was used as a loading
control. d The expression level of galectin-1 mRNA and protein was analyzed by RT-PCR (two upper panels) and western blotting (two lower panels)
after galectin-1 knockdown by a specific siRNA in 3T3-L1 cells. The mRNA and protein expression levels were normalized to those of β-actin.
e Detection of adipocyte differentiation of 3T3-L1 cells following galectin-1 silencing. The cells were treated with galectin-1 siRNA and differentiation
was induced by DMI treatment for 6 days. Oil red o (ORO) staining was performed to detect lipid accumulation (upper figures) and the staining level
was taken by picture. Cell morphology was detected (lower figures) by microscopy. Bars indicated 50 μm. f Measurement of lipid accumulation. The
ORO dye (used for staining) was eluted with 100% isopropanol and the optical density at 500 nm (OD500) was detected. ***p < 0.001 for the NC group
vs. the galectin-1 siRNA group.
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Interestingly, no difference was observed in BAT
weight between Lgals1−/− mice and wild-type mice when
both the groups were fed NFD and HFD (Fig. 5h).
However, the BAT weight ratio per body weight was
higher in HFD-fed Lgals1−/− mice than that of HFD-fed
wild-type mice (Fig. 4e). Thermogenesis, fatty acid oxi-
dation, and lipid accumulation and synthesis were pre-
viously reported to regulate the fat mass16. Therefore, the
expression levels of genes involved in thermogenesis and
fatty acid oxidation were measured in gWAT, iWAT and
BAT. Not only in BAT of HFD-fed Lgals1−/− mice, these
genes were significantly upregulated in both gWAT and
iWAT (Fig. 5c, f, and i). It suggested that depletion of
galectin-1 increased thermogenic gene expression to lead
resistance to obesity.
The expression of genes promoting hepatic
gluconeogenesis and lipogenesis is decreased in Lgals1−/−
mice
Because fatty liver diseases are often exhibited in obesity,
we conducted histological analysis of the liver. No
phenotypic differences were found in livers from both
NFD-fed Lgals1−/− mice and wild-type mice (Fig. 6a and
b). However, while a remarkable fat accumulation was
observed in the liver of HFD-fed wild-type mice, this
phenomenon was substantially attenuated in HFD-fed
Lgals1−/− mice. However, differences of liver weights were
detected slightly in the between Lgals1−/− mice and wild-
type mice, after HFD exposure (Fig. 6a). The expression of
genes involved in gluconeogenesis, such as glucose-6-
phosphatase (G6PC) and phosphoenolpyruvate carbox-
ykinase (PCK), were significantly reduced in the livers of
HFD-fed Lgals1−/− mice (Fig. 6c). The expression of
FASN, ACC1, and SCD1 (genes involved in lipogenesis)
were also downregulated in HFD-fed Lgals1−/− mice
(Fig. 6c). Moreover, macrophage markers (F4/80) and pro-
inflammatory cytokines (TGFβ, TNFα, CCL2 and CCL3)
were found to be significantly downregulated in the livers
of HFD-fed Lgals1−/− mice compared to their Lgals1+/+
counterparts (Fig. 6d). It suggested that depletion of
galectin-1 significantly reduced fat accumulation and
inflammatory cytokine secretion in liver.
Fig. 2 Galectin-1 knockdown inhibited adipocyte differentiation. a Detection of mitotic clonal expansion during adipocyte differentiation. Cells
were counted by viewing with microscopy at 0 and 48 h after inducing adipocyte differentiation. b The mRNA expression level of adipogenic and
lipogenic factors, such as PPARγ, C/EBPα, FASN and FABP4 was analyzed by quantitative RT-PCR in 3T3-L1 cells, with or without galectin-1 silencing.
Data are presented as the mean ± SEM (n= 3 for each lane). ***p < 0.001 for the NC group vs. the Lgals1 siRNA treated group. c The protein
expression level of adipogenic and lipogenic factors was analyzed by western blotting in 3T3-L1 cells, with or without galectin-1 silencing. β-actin
expression was used as a loading control. d Detection of adipocyte differentiation of 3T3-L1 cells in the absence or presence of lactose (25, 50, or
100 mM). Adipocyte differentiation was induced by treating the cells with DMI and lactose for 6 days. Cell morphology was detected by microscopy.
Bars indicated 50 μm. e Measurement of lipid accumulation. The ORO dye (used for staining) was eluted with 100% isopropanol and the OD500 was
measured.
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Discussion
The prevalence of obesity is rapidly growing worldwide.
Obesity is known to increase the rate of mortality through
an elevated risk of developing several chronic conditions,
such as T2D, cardiovascular disease, osteoarthritis,
dementia, and cancer, as well as to exacerbate the severity
of various acute diseases17. Here, we addressed the role of
galectin-1 in obesity. Galectins are involved in various
aspects of biological homeostasis and their role in cancer
and inflammatory diseases has been extensively investi-
gated18–21. Galectins also represent a potential ther-
apeutic target for obesity17. The role of galectin-1 in
obesity has also been also explored14,22. However, the
exact function of galectin-1 in the context of obesity is
still unknown.
In this study, we observed that higher expression of
galectin-1 was detected in adipose tissues of HFD-fed mice
than in those of NFD-fed mice. Galectin-1 also increased
during adipocyte differentiation and lipid accumulation12.
It was reported that treatment with thiogalactoside
(TDG)14 or lactulose22 reduced adipocyte differentiation
and obesity in murine fed a HFD. TDG and lactulose is a
non-metabolized disaccharide that can bind to galectins,
and inhibit the function of intracellular and extracellular
galectins23. In this study, the inhibition of extracellular
galectins by lactose did not affect adipocyte differentiation.
It was reported that extracellular galectin-1 stimulates
angiogenesis in vitro and in vivo, and these effects were
inhibited by lactose treatment11. Our finding suggested
that the regulation of adipocyte differentiation by galectin-
1 was based on an intracellular mechanism. Next, we
determined that the expression of galectin-1 protein
increased in both the nucleus and cytoplasm after induc-
tion of adipocyte differentiation. The increased nuclear
localization of galectin-1 during adipocyte differentiation
further supports this conclusion. Moreover, we provided
the first evidence of an interaction between galectin-1 and
PPARγ. Galectin-1 overexpression elevated PPARγ
expression and PPRE activity. Based on these results, we
suggested that nuclear galectin-1 may promote adipocyte
differentiation by interacting with PPARγ, which is a major
transcription factor modulating several biological
Fig. 3 Galectin-1 interacted with PPARγ. a Detection of localization of galectin-1 and PPARγ after DMI treatment in preadipocyte 3T3-L1 cells by
confocal microscopy. Galectin-1 was stained with cy5-conjugated antibody and PPARγ with FITC-conjugated antibody. DAPI was used for nuclear
staining. Bars indicated 50 μm. b Cellular localization and expression level of galectin-1 and PPARγ were analyzed by western blotting using nuclear
and cytosolic fractions of 3T3-L1 cells. GAPDH and Lamin A/C expression levels were detected and used as loading controls. c Immunoprecipitation
of galectin-1 and PPARγ was performed in human embryonic kidney 293 (HEK293) cells. Cell lysates were immuneprecipitated using anti-Flag beads.
β-actin expression was detected by western blotting as a loading control. d Flag-tagged galectin-1 overexpression vector was transfected in HEK293
cells and endogenous PPARγ expression was detected by western blotting. β-actin expression was used as a loading control. e Detection of luciferase
activity of PPAR-response element (PPRE) by galectin-1 overexpression. Luciferase activity of PPRE was normalized to β-gal activity. Data are
presented as the mean ± SEM. **p < 0.01 for the mock-transfected group vs. the galectin-1-overexpression group.
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processes that are perturbed in obesity, including inflam-
mation, lipid and glucose metabolism, and overall energy
homeostasis24. The high relevance of these processes
explains the strong interest in PPAR agonists and
antagonists in medical research and drug discovery25.
Thus, our data identify galectin-1 as a potential regulator of
PPARγ. It is also suggested that targeting galectin-1 may
represent a new way to treat a wide spectrum of metabolic
diseases by modulating PPARγ activity.
We further determined the metabolic phenotype in
galectin-1-deficient (Lgals1−/−) mice that were fed a 60%
high-fat diet (HFD). Lgals1−/− mice showed decreased
body weights and adipose tissues mass compared to those
of wild-type (Lgals1+/+) mice, following HFD adminis-
tration. Downregulation of genes involved in adipogenesis,
fatty acid uptake, and lipogenesis were detected in both
gWATs and iWATs of Lgals1−/− mice. Interestingly, the
expression of genes involved in thermogenesis and fatty
acid oxidation were increased in WATs and BATs from
Lgals1−/− mice. Obesity causes decreased thermogenesis
and fatty acid oxidation26,27. Therefore, these two pro-
cesses are potential therapeutic targets for obesity28–30. In
Lgals1−/− mice, decreased lipogenesis, as well as increased
thermogenesis and fatty acid oxidation, resulted in a
synergistic inhibition of body weight gain. Further studies
should be conducted to establish whether the increase in
thermogenesis induced by galectin-1 knockdown involves
the β-adrenergic signaling, which typically regulates the
expression of thermogenic genes28,29.
Lgals1−/− mice exhibited lower fasting glucose levels than
those in the wild-type counterparts, supposed to be resulted
in an improvement of diabetes. The expression of macro-
phage markers and pro-inflammatory cytokines were also
decreased in the adipose tissues of Lgals1−/− mice. Insulin
resistance in obesity is known to be associated with an
increased inflammation in adipose tissue31,32. The reduced
inflammation observed in the adipose tissues of Lgals1−/−
mice suggested that galectin-1 targeting improved insulin
resistance. A previous study conducted in non-obese dia-
betic mice showed that treatment with soluble galectin-1
promotes the apoptosis of pathological Th1 cells, causing
pancreatic β-cell destruction33. Galectin-1 deficiency results
in pro-diabetic effects, suppressing the function of pan-
creatic B-cells and increasing inflammation of the adipose
tissues. In this study, we focused on lipogenesis and lipid
accumulation in the adipose tissue, but did not explore the
Fig. 4 Lgals1−/− mice were lean and showed reduced WAT masses. Both Lgals1+/+ and Lgals1−/− mice were fed a normal-fat diet (NFD) or a
high-fat diet (HFD) (60% fat) for 10 weeks (n= 5 per group). a Expression of galectin-1 mRNA was analyzed by RT-PCR in gonadal white adipose
tissue (gWAT), inguinal white adipose tissue (iWAT), brown adipose tissue (BAT), and liver samples from a NFD fed Lgals1+/+ and Lgals1−/− mice. b
Body sizes and weights were measured and presented as a picture and a body weight graph. c The increment of body weight for 10 weeks was
presented as a graph. d Daily food intake of Lgals1+/+ and Lgals1−/− mice fed a NFD or a HFD. e Ratio of gWAT, iWAT, and BAT weights to body
weights of Lgals1+/+ and Lgals1−/− mice fed a NFD or a HFD. f Levels of serum glucose, triglycerides, and free fatty acids in Lgals1+/+ and Lgals1−/−
mice fed a NFD or a HFD. Data are presented as the mean ± SEM *p < 0.05, **p < 0.01, and ***p < 0.001 for the Lgals1+/+ mice vs. the Lgals1−/− mice.
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function of pancreatic β-cells or insulin resistance. Further
studies focusing on the role of galectin-1 in glucose home-
ostasis will be necessary to clarify the impact of galectin-1 on
diabetes.
We also found that Lgals1−/− mice liver have lower
expression of genes involved in gluconeogenesis, lipo-
genesis, and inflammation. Furthermore, we found that
hepatic triglyceride accumulation was also reduced in
Lgals1−/− mouse livers. It is unclear whether this result
reflects direct regulation by galectin-1 or an additional
effect of obesity resistance. A recent report showed that
the interaction of galectin-1 with neuropilin-1 promotes
liver fibrosis by activating the hepatic stellate cells34. In
addition, galectin-1 silencing was shown to inhibit the
activation and proliferation of mouse hepatic stellate cells
in a mouse model of liver fibrosis35. These results suggest
that galectin-1 may have a direct impact on both obesity
and liver disease.
Taken together, our findings suggest that galectin-1
expression increases during adipogenesis and accelerates
adipocyte differentiation and lipid accumulation. We
demonstrated that galectin-1 interacts with PPARγ and
promoted its expression and transcriptional activity.
Deletion of galectin-1 attenuated the effects of HFD on
blood glucose levels and inflammation and reduced the
body mass. In light of our results, the development of
Fig. 5 Lgals1−/− mice had decreased expression of lipogenic genes and increased expression of thermogenic genes in adipose tissues.
Both Lgals1+/+ and Lgals1−/− mice were fed a NFD or a HFD for 10 weeks (n= 5 per group) and their gWATs (a–d), iWATs (e–g) and BATs (h and i)
were prepared for experiments. a Size and weight of gWATs in Lgals1+/+ and Lgals1−/− mice fed a NFD or a HFD were measured and presented as a
picture and a graph. b Slide sections of gWAT from Lgals1+/+ and Lgals1−/− mice fed a NFD or a HFD were prepared and stained with H&E.
Morphology of adipocytes was presented as a picture. Bars indicated 100 μm. Size of adipocytes was measured using Image J software and
presented as a graph. c The expression of genes involved in fatty acid uptake, such as CD36 and FABP4, in lipogenesis, such as PPARγ, FASN, SREBF1,
in thermogenesis, such as CIDEA and PGC1α, and in fatty acid oxidation, such as ACOX1, CPT1 and PPARα in gWATs from Lgals1+/+ and Lgals1−/−
mice fed a HFD was analyzed by quantitative RT-PCR. d The expression of genes, included F4/80, a macrophage marker and pro-inflammatory
cytokines, such as TNFα, CCL2 and CCL3 in gWATs from Lgals1+/+ and Lgals1−/− mice fed a HFD was analyzed by quantitative RT-PCR. Data are
presented as the mean ± SEM ***p < 0.001 for the Lgals1+/+ mice vs. the Lgals1−/− mice. e Weight of iWATs in Lgals1+/+ and Lgals1−/− mice fed a
NFD or a HFD was measured and presented as a graph. f The expression of genes involved in adipogenesis, such as PPARγ, CEBPα and CEBPβ, in fatty
acid uptake, such as CD36 and FABP4, in lipogenesis, such as SREBP, ACC1, ACLY and SCD1, in thermogenesis, such as UCP1, PGC1α, PRDM16, CIDEA,
ADIPOQ, Elovl3 and COX2, and in fatty acid oxidation, such as PPARα and Mcad in iWATs from Lgals1+/+ and Lgals1−/− mice fed a HFD was analyzed
by quantitative RT-PCR. g The expression of genes, included F4/80, TNFα, CCL2 and CCL3 in iWATs from Lgals1+/+ and Lgals1−/− mice fed a HFD was
analyzed by quantitative RT-PCR. Data are presented as the mean ± SEM *p < 0.05 and **p < 0.01 for the Lgals1+/+ mice vs. the Lgals1−/− mice.
h Weight of BATs in Lgals1+/+ and Lgals1−/− mice fed a NFD or a HFD were measured and presented as a graph. i The expression of genes involved
in thermogenesis, such as UCP1, PGC1α, PRDM16, CIDEA, Elovl3 and COX2, and in fatty acid oxidation, such as PPARα and Mcad in iBATs from
Lgals1+/+ and Lgals1−/− mice fed a HFD was analyzed by quantitative RT-PCR. Data are presented as the mean ± SEM *p < 0.05 and **p < 0.01 for the
Lgals1+/+ mice vs. the Lgals1−/− mice.
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galectin-1 inhibitors should be considered as a therapeutic
strategy for obesity and other metabolic diseases. Further
studies are needed on this subject for their development.
Materials and methods
Cell culture and adipocyte differentiation
3T3-L1 and human embryonic kidney 293 (HEK293)
cells were purchased from the Korea Cell Line Bank
(Seoul, Korea). 3T3-L1 cells were maintained and differ-
entiated as previously described36,37. Briefly, the cells were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Welgene, Korea) supplemented with 10% calf
serum and 1% antibiotics at 37 °C in 5% CO2. Confluent
3T3-L1 cells were incubated for 48 h. Then, the medium
was replaced with DMEM supplemented with 10% fetal
bovine serum (FBS), dexamethasone (1 µM), insulin (1 µg/
ml), and isobutylmethylxanthine (520 µM). After 48 h, the
medium was replaced with DMEM supplemented with
10% FBS and insulin (1 µg/ml), and after an additional
48 h, the medium was replaced with DMEM supple-
mented with 10% FBS. HEK293 cells were maintained in
DMEM supplemented with 10% FBS and 1% antibiotics at
37 °C in 5% CO2.
RNA isolation and quantitative RT-PCR
Total RNA was prepared with the RNA lysis reagent
(Intron Biotechnology, Korea), following the manu-
facturer’s instructions. Complementary DNA (1 µg) was
synthesized using quantitative PCR master mix
(TOYOBO, Osaka, Japan). The following primer sets were
used for quantitative RT-PCR: ACC1, forward: 5′-
ATGCGATCTATCCGTCGGTG-3′ and reverse: 5′-
TCCTCCAGGCACTGGAACAT-3′; ACLY, forward: 5′-














Fig. 6 Lgals1−/− mice showed the amelioration of fatty liver phenotype. Both Lgals1+/+ and Lgals1−/− mice were fed a NFD or a HFD for
10 weeks (n= 5 per group). a Liver sizes and weights from Lgals1+/+ and Lgals1−/− mice fed a NFD or a HFD were analyzed and presented as a
picture and a graph. b Slide sections of liver from Lgals1+/+ and Lgals1−/− mice fed a NFD or a HFD were prepared and stained with H&E. Bars
indicated 100 μm. c The expression of genes involved in gluconeogenesis, such as G6PC and PCK, in fatty acid uptake, such as FABP1, CD36, PPARγ,
FATP2 and FATP5, in lipogenesis, such as SREBP, FASN, DGAT, ACC1 ACLY and SCD1, and in fatty acid oxidation, such as PPARα PGC1α, CAV1 and
ACOX1 in livers from Lgals1+/+ and Lgals1−/− mice fed a HFD was analyzed by quantitative RT-PCR. d The expression of genes, included F4/80, CCL2,
CCL3, TNFα and TGFβ in livers from Lgals1+/+ and Lgals1−/− mice fed a HFD was analyzed by quantitative RT-PCR. Data are presented as the mean ±
SEM *p < 0.05 and **p < 0.01 for the Lgals1+/+ mice vs. the Lgals1−/− mice.
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CIDEA, forward: 5′-CATACATCCAGCTCGCCCTT-3′
and reverse: 5′-CGTAACCAGGCCAGTTGTGA-3′; F4/




























Quantitative RT-PCR was performed using SYBR Premix
Ex Taq (Clontech Laboratories, Mountain View, CA,
USA) with ABI instruments (Applied Biosystems, Inc.,
Foster City, CA, USA). All expression results were nor-
malized to β-Actin expression.
Oil Red O (ORO) staining
Differentiated 3T3-L1 cells were washed with Dulbec-
co’s phosphate-buffered saline (PBS) and incubated in
10% formalin for 10min. Next, the cells were washed with
distilled water, and then with 60% isopropanol, and
completely dried. The ORO stock solution (0.35 g/100ml)
was diluted with isopropanol to prepare a 60% ORO
working solution. The dried cells were stained with the
ORO working solution for 30min and washed three time
with distilled water.
siRNA transfection
3T3-L1 cells were transfected with mouse galectin-1
siRNA (50 nM) using Lipofectamine RNAiMAX (Invi-
trogen, Carlsbad, CA, USA), according to the manu-
facturer’s protocol. After 24 h, the medium was replaced
with maintenance medium supplemented with 10% calf
serum38,39.
Western blot analysis
Cell lysates were prepared by using RIPA buffer (Bio-
sesang, Korea) containing a protease inhibitors cocktail
(GeneDEPOT, Barker, TX, USA) and phosphatase inhi-
bitor, incubated for 20min on ice and centrifuged at 4 °C
for 25min at 13 200 revolutions per minute (rpm). Each
supernatant was transferred to a new microcentrifuge
tube. The protein concentration in each supernatant was
measured with the protein assay reagent (Thermo Scien-
tific, Waltham, MA, USA). Protein samples were resolved
by sodium dodecyl sulfate (SDS)-polyacrylamide gel elec-
trophoresis and transferred to 0.45-µm polyvinylidene
fluoride membranes (Merck Millipore, Billerica, MA,
USA). The membranes were blocked with 5% skim milk
for 1 h at room temperature. After blocking, the mem-
branes were incubated overnight at 4 °C with primary
antibodies against galectin-1, PPARγ, C/EBPα, FASN,
FABP4, GAPDH, Lamin A/C or β-Actin (Santa Cruz
Biotechnology, Dallas, TX, USA) or against the Flag epi-
tope (Sigma-Aldrich, St. Louis, Missouri, USA). The
membranes were washed thrice for 10min with PBS
containing Tween 20 (PBST), and incubated for 1 h at
room temperature with the appropriate horseradish
peroxidase-conjugated secondary antibodies (Bethyl
Laboratories, Montgomery, TX, USA). Next, the mem-
branes were washed thrice for 10min with PBST. The
FUSION SOLO S Imaging System (Vilber, Eberhardzell,
Germany) was used for detection, according to manu-
facturer’s directions. β-Actin was used as a loading control.
Fractionation of cellular extracts
Nuclear and cytoplasmic extracts were prepared as
previously described40. 3T3-L1 cells were lysed in Buffer
A (10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl,
1 mM DTT, 0.2 mM phenylmethylsulfonyl fluoride
(PMSF), 0.1% NP-40), incubated for 15min on ice and
centrifuged at 4 °C for 10min at 850 relative centrifugal
force (rcf). Each supernatant (Cytosol) was transferred to
a new microcentrifuge tube. Remained pellets were lysed
in Buffer C (20 mM HEPES (pH 7.9), 25% glycerol, 0.42M
NaCl, 0.2 mM EDTA, 1.5 mM MgCl2, 1 mM DTT,
0.2 mM PMSF) and vortexed for 15 sec. The lysates were
incubated for 30 min on ice and vortexed every 10min for
15 sec. After centrifugation (4 °C for 10min at 13
200 rpm), Each supernatant (Nucleus) was transferred to a
new microcentrifuge tube. Nuclear and cytoplasmic
extracts were analyzed by western blotting. GAPDH and
Lamin A/C expression levels were detected and used as
loading controls.
Immunoprecipitation
Cell lysate extraction was performed with immunopre-
cipitation buffer as previously6. After centrifugation (4 °C
for 25min at 13 200 rpm), the supernatants were mixed
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with protein A/G agarose beads (Santa Cruz Biotechnol-
ogy), and precleared by incubation at 4 °C for 30min in a
rotor. After centrifugation (4 °C for 25min at 13 200 rpm),
anti-Flag beads (Sigma-Aldrich) were added to the
supernatants, followed by an overnight incubation at 4 °C
in a rotor. The immunoprecipitates were washed twice in
immunoprecipitation buffer, mixed with 2× SDS sample
buffer, and boiled at 100 °C for 5 min. After centrifugation
(4 °C for 2 min at 13 200 rpm), the supernatants were
analyzed by western blotting.
Luciferase reporter assay
PPRE-TK-Luc, pcDNA3 galectin-1, and β-gal were co-
transfected into HEK293 cells using Lipofectamine 2000
(Invitrogen). After 48 h, the cells were harvested and
luciferase activity was measured using the Luciferase
Assay System (Promega, Madison, Wisconsin, USA),
according to the manufacturer’s directions. Luciferase
activity was normalized using the β-gal Enzyme Assay
System (Promega).
Immunocytochemistry
3T3-L1 cells in chamber slides were fixed for 30 min
with 10% formalin at 4 °C, washed with 1× PBS, and
permeabilized in 0.5% Triton X-100 for 10min. Next, the
cells were incubated with primary antibodies at 4 °C, and
then with fluorescein isothiocyanate-conjugated anti-
mouse and cyanine 5-conjugated anti-rabbit secondary
antibodies (Invitrogen), as well as 4′,6-diamidino-2-phe-
nylindole (DAPI) staining solution (Vector Laboratories,
Burlingame, CA, USA). The images were analyzed by
confocal microscopy (LSM 700, Oberkochen, Germany).
Mouse studies
The animal studies were approved by the Yonsei Uni-
versity Health System Institutional Animal Care and Use
Committee (Permission number for animal experiments:
2015-0104). Galectin-1 knockout (Lgals1−/− C57BL/6
mice were purchased from the Knockout Mouse Project
Repository (Oakland, CA, USA). Wild-type (Lgals1+/+)
and galectin-1 knockout (Lgals1−/−) mice were bred as
heterozygotes in house and maintained on a C57BL/6
background. Heterozygous mice were bred with each
other to generate Lgals1+/+ and Lgals1−/− mice. Seven-
week-old male Lgals1+/+ and Lgals1−/− mice (5 per cage)
were fed a NFD or a HFD (Research Diets, Inc., New
Brunswick, NJ, USA) for 10 weeks. Littermate-matched
mice were randomly divided into 4 groups. All mice were
provided free access to food and water and kept on a 12 h
light/12 h dark cycle. Body weight and food intake were
measured once a week. After 10 weeks, mice were
euthanized with CO2 gas. Mouse tissues and serum were
stored at -80 °C before analysis. Portions of liver and
WAT were fixed in 10% formalin for histological analysis.
Immunohistochemical analysis of WATs and liver tissues
Mouse WATs and livers were fixed in 10% formalin and
embedded in paraffin. Paraffin-embedded WAT or liver
sections were subjected to hematoxylin and eosin (H&E)
staining. H&E-stained sections were analyzed using Image
J software41 (NIH, Bethesda, Maryland, USA).
Statistical analysis
The unpaired (two-sample) t-test was used to determine
the p-values. P-values < 0.05 were considered to reflect
statistically significant differences. Statistical analysis was
performed using Prism 5 (GraphPad software, La Jolla,
CA, USA).
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